Niche Immunology CRO Celentyx specializes in bespoke drug discovery services focused on human immunology across autoimmunity, inflammation, immuno-oncology, fibrosis and neuroinflammation, suggesting opportunities to partner on targeted target discovery and mechanism studies for immune-related therapies.

Human Primary Cells Access to human primary cells and patient-derived samples through hospital partnerships enables clinically relevant assays and translational readouts, presenting a compelling value proposition for customers requiring human-relevant data and biomarker insights.

Advanced Assay Platforms Integrated capabilities in multi-colour flow cytometry, CyTOF, high-content imaging, multiplex analysis and proteomics position Celentyx to support complex profiling, screening and mechanism-of-action studies for immunology-focused programs.

Strategic Academic Ties proximity to Oxford and Birmingham translational medicine expertise offers collaboration and credibility, potentially opening co-development, sponsored research, or milestone-based engagements with larger pharma seeking academic-backed resources.

Early Revenue Opportunity Current revenue under one million indicates room to scale through tiered service packages, repeat engagements, and expanded offerings (biomarker discovery, readouts, and platform extensions) targeting mid-sized biotechs and pharma companies advancing immunology programmes.